Shawn Singh: "We are also exploring the therapeutic potential of itruvone, a differentiated therapy that can expedite relief for patients suffering from major depressive disorder......."
— Shawn Singh
03Detailed Report
VTGN
VistaGen Therapeutics Inc
Period
Q4 2024
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 25, 2026
Swipe to view all report sections
Executive Summary
In Q4 2024, VistaGen Therapeutics Inc reported a revenue of $197,300, a notable decline compared to previous quarters due to the transitional phase of clinical trials. The company achieved significant milestones, especially with its PALISADE-2 Phase 3 trial validation, marking a pioneering achievement in treating social anxiety disorder (SAD). However, losses continue to reflect the heavy R&D investments, totaling approximately $7.4 million in this quarter. Looking ahead, management is optimistic about advancing the PALISADE-3 trial and the potential market impact of their pipeline, while also addressing the ongoing cash burn and operational efficiency in this competitive biotech landscape.
Key Performance Indicators
Revenue
Increasing
197.30K
QoQ: -52.04% | YoY: 12.36%
Gross Profit
Increasing
197.30K
1.00% margin
QoQ: -52.04% | YoY: 12.36%
Operating Income
Increasing
-11.36M
QoQ: -44.08% | YoY: 7.19%
Net Income
Increasing
-9.52M
QoQ: -49.95% | YoY: 22.13%
EPS
Increasing
-0.35
QoQ: 18.60% | YoY: 79.53%
Revenue Trend
Margin Analysis
Financial Highlights
### Revenue Performance
- Revenue: $197,300 (down 52.04% QoQ), signaling transitions in trial phases rather than commercial traction.
- Gross Profit: $197,300.
### Profitability Metrics
- EBITDA: -$11,212,800, related to significant expenditures in clinical trials.
- Net Income: -$9,521,400 (Net Income Ratio: -48.26%).
- EPS: -$0.35, consistent with the loss trajectory but shows a year-over-year improvement in percentage terms.
### Cash Flow and Balance Sheet
- Cash at End of Period: $119,166,000, supporting ongoing operations.
- Total Liabilities: $9,367,000 against a strong equity base of $114,286,000.
- Current Ratio: 23.54, indicating substantial liquidity to cover short-term obligations.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
197.30K
12.36%
-52.04%
Gross Profit
197.30K
12.36%
-52.04%
Operating Income
-11.36M
7.19%
-44.08%
Net Income
-9.52M
22.13%
-49.95%
EPS
-0.35
79.53%
18.60%
Key Financial Ratios
Gross Profit Margin
Weak
1.00%
Gross profit margin is below industry norms, profitability concerns
Operating Profit Margin
Weak
-57.57%
Operating margin is below industry norms, profitability concerns
Net Profit Margin
Weak
-48.26%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.08%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.08%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
23.54
Current ratio indicates excellent liquidity and financial flexibility
Debt to Equity
Conservative
0.02
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-3.83x
Negative earnings make P/E ratio not meaningful
Price to Book
Fair Value
1.28x
Price-to-book ratio reasonable for profitable companies
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.